Table 1. Baseline characteristics of participants.
CharacteristicPlacebo (n = 16)Vaccine (n = 14)Total (n = 30)
Sex, no. (%)
  Male16 (100)14 (100)30 (100)
Age, years
  Median (interquartile range)42 (32, 48)40 (44, 26)41.5 (46, 31)
  Range24–6521–6021–65
Inclusion criteria met*, no. (%)
  Acute infection6 (38)3 (21)9 (30)
  Early infection10 (62)11 (78)21 (70)
Reported seroconversion illness, no. (%)9 (56)9 (64)18 (60)
Time between HIV diagnosis and start of ART, days
  Median (interquartile range)25 (8, 53)28 (3, 73)28 (18, 46)
  Range0–883–730–88
Duration of HIV suppression on ART at study entry, years
  Median (interquartile range)4.8 (2.7, 10.3)2 (1.7, 3.2)3 (1.8, 6.6)
  Range1.1–131.2–191.1–19
CD4+ count, cells/mm3 at study entry
  Median (interquartile range)758 (596, 1165)726 (610, 942)749 (604, 942)
  Range501–2162363–1017363–2162
Viral clade
  B151227
  A/G022
  Unknown101

*See Materials and Methods for acute and early infection inclusion criteria.

P = 0.0526.